High blood pressure, frequently dubbed the silent killer, affects over a billion people worldwide, serving as a primary catalyst for cardiovascular emergencies such as strokes, heart attacks, and renal failure. For decades, the global medical community has grappled with the reality that a significant proportion of hypertension cases are secondary—meaning they are driven by an underlying, treatable medical condition rather than idiopathic factors. Among these, primary aldosteronism has long been recognized as a major culprit, yet it remains chronically underdiagnosed. A landmark international study published in Science Translational Medicine now offers a paradigm-shifting solution, demonstrating that a lightweight wearable device can detect previously hidden hormonal fluctuations that occur during sleep, fundamentally altering how medicine may diagnose and treat this widespread disorder.
Unmasking Primary Aldosteronism: The Scale of the Problem
Primary aldosteronism is an endocrine disorder characterized by the overproduction of aldosterone, a vital hormone synthesized by the adrenal glands that regulates salt and water balance within the body, thereby controlling blood pressure and blood volume. When the adrenal glands malfunction and secrete excessive amounts of aldosterone, the kidneys retain sodium and excrete potassium, leading to systemic fluid retention, vascular inflammation, and elevated blood pressure.
Current clinical guidelines from organizations such as the Endocrine Society recommend screening for primary aldosteronism in all patients diagnosed with hypertension. Epidemiological data indicates that the condition affects up to one in five individuals living with high blood pressure. Despite this high prevalence, only a minute fraction of these patients ever receive a definitive diagnosis. The consequences of this diagnostic gap are severe. Untreated primary aldosteronism accelerates vascular damage, placing patients at a vastly elevated risk of coronary artery disease, atrial fibrillation, stroke, and diabetes compared to those with conventional primary hypertension.
The core difficulty in identifying primary aldosteronism lies in its elusive biochemistry. Traditional diagnostic protocols rely on a single blood test administered during daylight hours to measure aldosterone and renin levels. However, medical researchers have increasingly suspected that aldosterone secretion is not uniform throughout the day. Because standard clinical workflows require patients to visit a hospital or laboratory for intermittent blood draws, clinicians have historically relied on snapshots of a patient’s endocrine profile, completely missing the dynamic shifts that occur over a full 24-hour cycle.
A Chronological Breakthrough: The 24-Hour Wearable Trial
To address these diagnostic blind spots, a multidisciplinary consortium of researchers from the University of Bristol and the University of Manchester in the United Kingdom, the University of Bergen in Norway, alongside clinical collaborators in Stockholm and Athens, designed a rigorous proof-of-concept investigation.
The study enrolled 60 patients distributed across clinical centers in Bristol, Bergen, Stockholm, and Athens. Over a continuous 24-hour monitoring period, participants were fitted with a specialized, lightweight wearable device roughly the size of a modern smartphone, which attaches comfortably at the waist. Unlike cumbersome hospital telemetry systems or frequent intravenous needle draws that disrupt normal routines, this portable apparatus samples hormones directly from the skin interstitium, allowing patients to move freely, engage in daily activities, and, crucially, sleep undisturbed in their own homes.
The underlying technology, designated as U-RHYTHM, was originally invented by Professor Stafford Lightman at the University of Bristol and was subsequently adopted and advanced by the spinout enterprise Dynamic Therapeutics in 2023. By automating frequent sampling—obtaining hormone measurements every 20 minutes across the full circadian cycle—the research team amassed unprecedented high-resolution data sets detailing the real-time ebb and flow of aldosterone, alongside two closely related steroid hormones: 18-hydroxycortisol and 18-oxocortisol.
Unveiling Nocturnal Surges and Diagnostic Flaws
The analysis of this continuous 24-hour data revealed a startling physiological phenomenon that had eluded modern medicine for generations: patients with primary aldosteronism experience dramatic, repeated bursts of hormone production during the night, even while their overall circadian day-night rhythm remains fundamentally intact.
These nocturnal surges originate directly from the adrenal glands and are particularly pronounced in patients whose disease stems from a unilateral source—meaning the overproduction of aldosterone is driven by an abnormality confined to a single adrenal gland rather than both. To validate these findings, the research team observed that these abnormal hormonal spikes vanished entirely following the surgical removal of the affected adrenal gland, confirming a direct pathophysiological link between the nocturnal bursts and the disease state itself.
These revelations expose a profound vulnerability in contemporary endocrinology. Because aldosterone does not remain consistently elevated throughout the day and night, standard single-point blood tests frequently yield false negatives. In many severe cases captured by the U-RHYTHM device, hormone levels periodically plummeted below the conventional diagnostic thresholds during daylight hours. A routine morning blood test taken during one of these cyclical lulls would easily categorize a severely ill patient as normal, leaving a dangerous endocrine disorder to silently damage the cardiovascular system unchecked.
Expert Insights and Clinical Perspectives
The implications of this international research have drawn widespread praise from the clinical community, signaling an impending shift in how hypertension clinics approach secondary causes.
Dr. Thomas Upton, Clinical Research Fellow in Automated Sampling at the University of Bristol and Senior Clinical Fellow at Bristol Hospitals NHS Foundation Trust, served as study co-lead author. Emphasizing the clinical burden of the condition, Dr. Upton noted that primary aldosteronism represents the single most common cause of secondary hypertension encountered in specialized blood pressure clinics, potentially impacting millions of individuals in the United Kingdom alone.
"Due to the way hormones change during the day and the current complexity of the diagnostic process, diagnosis is often delayed or never made at all," Dr. Upton stated. He emphasized that monitoring patients at home during normal daily activities provides a realistic window into true physiological rhythms. "This approach could potentially revolutionize how we diagnose hypertension and ultimately reduce cardiovascular disease—particularly heart disease and strokes—that could have have been prevented."
Echoing these sentiments, study senior author Dr. Eder Zavala, a UKRI Future Leader Fellow at the University of Manchester, underscored the power of advanced mathematical and computational analytics in interpreting high-resolution endocrine data. "By continuously monitoring hormones over 24 hours, we were able to reveal a previously hidden pattern of nocturnal hormone bursts," Dr. Zavala explained. "This gives us a much clearer understanding of the disease and could ultimately help doctors detect it earlier and treat patients more effectively. A more detailed mathematical and computational analysis of daily hormonal profiles could eventually also help uncover earlier and more subtle forms of the disease, opening new opportunities to improve outcomes for patients living with high blood pressure."
Professor Stafford Lightman, Professor of Medicine at the University of Bristol and inventor of the core U-RHYTHM technology, stressed that the medical community must reevaluate standard diagnostic protocols. "The findings suggest that clinicians may need to rethink how they look for the disorder," Prof. Lightman remarked. He advocated for a transition away from isolated blood draws and toward continuous rhythm tracking, particularly focusing on the overnight patterns that hold crucial diagnostic clues. He noted that further clinical trials are now required to establish formalized pathways integrating dynamic hormone measurement into routine practice.
Broader Implications and Future Horizons
The successful validation of continuous wearable hormone monitoring opens transformative pathways for preventive medicine. Cardiovascular disease remains a leading cause of global mortality, and hypertension is its most formidable driver. While essential hypertension—high blood pressure with no identifiable secondary cause—often requires lifelong pharmacological management, primary aldosteronism offers a rare window of curability. When the disease is driven by a single hyperactive adrenal gland, minimally invasive laparoscopic surgery can completely cure the condition, normalizing blood pressure and eliminating the need for lifelong multi-drug regimens.
By utilizing wearable technology to identify unilateral disease manifestations that standard diagnostics miss, clinicians can successfully triage patients for curative surgical interventions much earlier in the disease trajectory. Even for patients with bilateral adrenal hyperplasia—where surgery is not the primary option—early and precise characterization of hormonal rhythms allows for targeted pharmacotherapy using mineralocorticoid receptor antagonists, tailored specifically to the patient’s individual endocrine profile rather than a generalized one-size-fits-all dosage.
As healthcare systems globally face mounting economic pressures from chronic disease management, innovations that streamline diagnostics and prevent catastrophic cardiovascular events represent a vital frontier. The transition from static snapshots to continuous dynamic monitoring marks a fundamental evolution in clinical endocrinology, promising a future where hidden hormonal drivers of hypertension can be intercepted long before irreversible organ damage occurs.
Funding for this transformative research was provided by a robust coalition of international scientific organizations, including EU Horizon 2020, the Trond Mohn Foundation, the UKRI Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council, University Hospitals Bristol and Weston NHS Foundation, the Swedish Medical Research Council, and the Knut and Alice Wallenberg Foundation. These findings directly support the University of Bristol’s overarching research ‘Grand Challenge’ initiative focused on understanding and preventing cardiovascular disease, while building upon National Institute for Health and Care Research (NIHR)-funded programs dedicated to the earlier identification of hypertension and related metabolic risk factors.
